Belongs to

• Solid Tumor Oncology Division

Types of Work

["2019"]

[[["Meeting Abstracts",236],["Journal Articles",210],["Reviews",7],["Editorials",5],["Research Letters",3],["Miscellaneous",2],["Book Sections",1]]]

[464]

Popular keywords

• adult
• aged
• article
• female
• gene mutation
• human
• humans
• major clinical study
• male
• priority journal

Recent Works

1. eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer

   Journal Article

   Boyer, J. A.; Rosen, E. Y.; Sharma, M.; Dorso, M. A.; Mai, N.; Amor, C.; Reiter, J. M.; Kannan, R.; Gadal, S.; Xu, J.; more...
   Proceedings of the National Academy of Sciences of the United States of America (2025)

   Fulltext@MSK | Save
2. Updated efficacy of mutant-selective PI3Kα inhibitor RLY-2608 in combination with fulvestrant in patients with PIK3CA-mutant HR+HER2-advanced breast cancer: ReDiscover trial

   Meeting Abstract

   Sammons, S. L.; Manich, C. S.; Italiano, A.; Schram, A. M.; Ortega, P. T.; Schott, A. F.; Guerrero, A.; Aix, S. P.; Nanda, R.; Wisinski, K. B.; more...
   Journal of Clinical Oncology (2025)

   Fulltext@MSK | Save
3. Beamion PANTUMOR-1: A phase II, multicenter, multicohort, open-label trial to evaluate the efficacy and safety of the oral HER2-selective tyrosine kinase inhibitor zongertinib for the treatment of HER2 -mutated or overexpressed/amplified solid tumors

   Meeting Abstract

   Schram, A. M.; Clay, T. D.; Prenen, H.; Park, J. J.; Lunger, L.; Hussain, J.; Maier, D.; Kitano, S.; Dumbrava, E. E.; Kim, H. D.; more...
   Journal of Clinical Oncology (2025)

   Fulltext@MSK | Save